The pharma industry felt the PLI scheme leads the way to create more global-scale pharma companies in India. The industry expects more guidelines to come out on minimum investment criterion to qualify for the scheme. If the Centre only links the incentive to incremental sales value, the industry is happy, said an industry insider.
Ramesh Swaminathan, chief financial officer and head of corporate affairs at Lupin, said, they are eagerly awaiting the finer details of the scheme. Meanwhile, B R Sikri, chairman of the Federation of Pharma Entrepreneurs, said, higher incentives would have meant more production of cancer drugs, thereby, bringing down their prices.
The large pharma firms are keen to take part in the scheme, says Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance, that represents the country’s largest 24 pharma firms.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU